<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Romoff MR</submitter><funding>National Institute of Arthritis and Musculoskeletal and Skin Diseases</funding><funding>National Institute of Allergy and Infectious Diseases</funding><funding>NIAID NIH HHS</funding><funding>NHGRI NIH HHS</funding><funding>NIAMS NIH HHS</funding><funding>National Institute of General Medical Sciences</funding><funding>National Human Genome Research Institute</funding><funding>NIGMS NIH HHS</funding><pagination>e193054</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12643496</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(22)</volume><pubmed_abstract>In the rheumatoid arthritis (RA) synovium, resident fibroblast-like synoviocytes (FLS) express MHC class II molecules (HLA-D) but lack the costimulatory signals typically required for T cell activation. Here, we demonstrate that antigen presentation by FLS induces a distinct T cell activation state characterized by high CD69 yet reduced CD25 and HLA-DR expression, suppressed proliferation, and decreased effector cytokine production compared with professional antigen-presenting cells (APCs), such as macrophages. FLS were also capable of suppressing macrophage-induced T cell activation, underscoring their dominant immunomodulatory role in the synovial microenvironment. Mechanistically, we identify indoleamine 2,3-dioxygenase-mediated (IDO1-mediated) tryptophan depletion as the primary driver</pubmed_abstract><journal>JCI insight</journal><pubmed_title>Rheumatoid arthritis synovial fibroblasts modulate T cell activation.</pubmed_title><pmcid>PMC12643496</pmcid><funding_grant_id>AI034206-28</funding_grant_id><funding_grant_id>U01 HG012103</funding_grant_id><funding_grant_id>R37 AI034206</funding_grant_id><funding_grant_id>T32 AR071302</funding_grant_id><funding_grant_id>T32 5T32AR071302-04</funding_grant_id><funding_grant_id>R01 AI148435</funding_grant_id><funding_grant_id>R01 AI034206</funding_grant_id><funding_grant_id>AI148435</funding_grant_id><funding_grant_id>T32GM152349</funding_grant_id><funding_grant_id>T32 GM152349</funding_grant_id><pubmed_authors>Smith MH</pubmed_authors><pubmed_authors>DiCarlo EF</pubmed_authors><pubmed_authors>Periyakoil PK</pubmed_authors><pubmed_authors>Ramirez D</pubmed_authors><pubmed_authors>Leslie CS</pubmed_authors><pubmed_authors>Goodman SM</pubmed_authors><pubmed_authors>Donlin LT</pubmed_authors><pubmed_authors>Rudensky AY</pubmed_authors><pubmed_authors>Romoff MR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Rheumatoid arthritis synovial fibroblasts modulate T cell activation.</name><description>In the rheumatoid arthritis (RA) synovium, resident fibroblast-like synoviocytes (FLS) express MHC class II molecules (HLA-D) but lack the costimulatory signals typically required for T cell activation. Here, we demonstrate that antigen presentation by FLS induces a distinct T cell activation state characterized by high CD69 yet reduced CD25 and HLA-DR expression, suppressed proliferation, and decreased effector cytokine production compared with professional antigen-presenting cells (APCs), such as macrophages. FLS were also capable of suppressing macrophage-induced T cell activation, underscoring their dominant immunomodulatory role in the synovial microenvironment. Mechanistically, we identify indoleamine 2,3-dioxygenase-mediated (IDO1-mediated) tryptophan depletion as the primary driver</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T18:41:07.573Z</modification><creation>2026-05-20T03:13:32.917Z</creation></dates><accession>S-EPMC12643496</accession><cross_references><pubmed>41055954</pubmed><doi>10.1172/jci.insight.193054</doi></cross_references></HashMap>